August 4, 2022 07:28 AM EDTUpdated 08:49 AM

Pfizer terminates PhIII study of rare cardiovascular drug picked up in $11.4B Array acquisition

Kyle LaHucik

Senior Reporter

While Pfizer’s $11.4 billion acquisition of Array BioPharma in the summer of 2019 was mainly focused on oncology, namely Braftovi and Mektovi, there were …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer terminates PhIII study of rare cardiovascular drug picked up in $11.4B Array acquisition

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Pfiz­er ter­mi­nates PhI­II study of rare car­dio­vas­cu­lar drug picked up in $11.4B Ar­ray ac­qui­si­tion

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Pfizer terminates PhIII study of rare cardiovascular drug picked up in $11.4B Array acquisition